印度 HPV（人类乳突病毒）疫苗市场评估：依类型、适应症、合成、分销管道和地区划分的机会和预测（2017-2031 年）

根据预测，印度HPV（人类乳突病毒）疫苗市场规模将从2023年的13亿美元成长到2031年的30亿美元，2024-2031年预测期间复合年增长率为11%。

有几个因素促使了市场规模的扩大，包括由于子宫颈癌和其他 HPV 相关疾病的盛行率不断增加，人们对 HPV 疫苗接种重要性的认识不断提高。此外，政府主导的各种措施、疫苗接种计划和疫苗开发技术的进步在提高疫苗接种意识方面发挥着重要作用。

近年来，由于人们对预防 HPV 感染及相关疾病重要性的认识不断提高，印度 HPV 疫苗市场经历了显着增长。子宫颈癌是影响印度数百万女性的主要原因，主要与 HPV（一种常见的性传染感染）有关。人们越来越认识到 HPV 疫苗的好处及其减轻子宫颈癌负担的潜力，促使印度对 HPV 疫苗的需求激增。为此，印度政府和各医疗机构实施了一系列措施和疫苗接种计划，以加速疫苗的接种，特别关注年轻妇女和女孩。

此外，随着疫苗开发技术的进步，印度 HPV 市场有望推出更有效、更容易取得的疫苗。这些突破让医疗保健提供者和个人对 HPV 疫苗接种的有效性和安全性充满了信心。HPV 疫苗在印度日益普及，标誌着全国在对抗 HPV 感染和保护妇女福祉的努力中取得了可喜的进展，对印度 HPV 疫苗市场产生了积极影响。

2023 年 12 月，印度计划生育协会 (FPAI) 发起了全国性 HPV 疫苗接种运动，以保护女孩和妇女免受子宫颈癌的侵害。该活动旨在透过 FPAI 遍布全国的 40 个分支机构为 20,000 多名妇女和女孩接种疫苗。

本报告调查了印度 HPV（人类乳突病毒）疫苗市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。格局、领导企业简介等等。

目录

第一章研究方法论

第二章 专案范围与定义

第 3 章执行摘要

第四章 印度HPV（人类乳突病毒）疫苗市场展望

• 市场规模/预测
• 依类型
  • 二价
  • 四价
  • 非价的
• 依指示
  • 子宫颈癌
  • 肛门癌
  • 外阴/阴道癌
  • 阴茎癌
  • 口咽癌
  • 其他
• 依合成方法
  • 基于核酸的
  • 基于胜□的
  • 基于蛋白质的
  • 基于细胞的
  • 活载体疫苗
• 依分销渠道
  • 医院
  • 零售药店
  • 网上药店
  • 非政府组织
• 依地区
  • 北方
  • 南部
  • 东
  • 西部/中部地区
• 依公司划分的市场占有率

第 5 章 市场测绘

• 依类型
• 依疾病分类
• 依合成方法
• 依分销渠道
• 依地区

第六章 宏观环境与产业结构

• 供需分析
• 进出口分析
• 价值链分析
• PESTEL 分析
• 波特五力分析

第七章市场动态

• 生长促进因子
• 生长抑制因素（问题/限制）

第八章 监理框架与创新

• 临床试验
• 专利情况
• 监管审批
• 创新/新兴技术

第九节 主要公司状况

• 前 5 名市场领导者的竞争矩阵
• 前 5 名市场领导者的市场收入分析
• 併购/合资（如适用）
• SWOT分析（5家参与企业）
• 专利分析（如果适用）

第10章价格分析

第11章案例研究

第十二章 主要公司展望

• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Beijing Health Guard Biotechnology, Inc.
• China National Biotec Group Company Limited
• Shanghai Bovax Biotechnology Co., Ltd.
• Walvax Biotechnology Co., Ltd
• Xiamen Innovax Biotech Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Eyegene Inc.
• Janssen Biotech, Inc.

第十三章 战略建议

第14章关于我们公司/免责声明

India human papillomavirus vaccine market is projected to witness a CAGR of 11% during the forecast period FY2024-FY2031, growing from USD 1.3 billion in FY2023 to USD 3 billion in FY2031. Several factors are contributing to the growing market size, including a rise in awareness about the importance of HPV vaccination due to the increasing prevalence of cervical cancer and other diseases associated with HPV. In addition, various government-led initiatives and vaccination programs, as well as advancements in vaccine development technology, have played a crucial role in increasing awareness about vaccination.

In recent years, India human papillomavirus vaccine market has experienced substantial growth, driven by an increasing recognition of the significance of preventing HPV infections and their associated diseases. Cervical cancer, a leading cause of concern for millions of women in India, is primarily linked to HPV, a common sexually transmitted infection. The increasing awareness about the benefits of HPV vaccination and its potential to reduce the burden of cervical cancer has resulted in a surge in demand for HPV vaccines in India. In response, the Indian government and various healthcare organizations have undertaken numerous initiatives and vaccination programs to promote widespread vaccine adoption, with a particular focus on young girls and women.

Furthermore, advancements in vaccine development technology have paved the way for the introduction of more effective and accessible vaccines in India human papillomavirus vaccine market. These breakthroughs have instilled confidence among healthcare providers and individuals regarding the efficacy and safety of HPV vaccination. The rising popularity of HPV vaccines in India signals a promising step forward in the effort to combat HPV infections and safeguard the well-being of women across the country, positively impacting the India human papillomavirus vaccine market.

In December 2023, the Family Planning Association of India (FPAI) initiated a nationwide HPV vaccination drive for girls and women to protect them against cervical cancer. The campaign's objective is to vaccinate over 20,000 women and girls through the FPAI's 40 branches spread across the country.

Increasing Awareness About HPV Immunization

Increasing awareness about the importance of HPV vaccination has led to significant growth of India human papillomavirus vaccine market. While efforts implemented by governments and healthcare organizations have increased screening for cervical cancer, the primary prevention achieved through HPV immunization has played a crucial role in diminishing the cervical cancer burden in India. The effectiveness of these strategies has been evident not only in high-income countries (HICs) but has also resulted in higher rates of adoption of the HPV vaccine and widespread approval in low- and lower-middle-income countries (LLMICs). International collaborations between WHO, United Nations Population Fund, UN Women, and the IPVS (Indian Post Visibility System), along with healthcare providers who are trusted sources of health advice, persist in their efforts to inform and promote HPV immunization. In the context of school-based vaccination programs, educators, school administrators, and the Ministry of Education also play a crucial role in conveying the advantages of HPV vaccination.

Increasing Incidence of HPV-related diseases

According to the National Cancer Registry Programme of the Indian Council of Medical Research, the estimated number of cervical cancer cases in India was over 340,000 in 2023. The incidence will further increase in the coming years because of factors such as smoking and excessive alcohol consumption, urbanization and changing lifestyles, delayed childbearing and multiple sexual partners, limited access to quality healthcare and diagnostic facilities in certain regions of India, and cultural taboos and stigmatization of certain cancers and sexually transmitted infections. This way, increasing incidences of HPV-related diseases will continue to have a positive effect on India human papillomavirus vaccine market.

Government Initiatives

Government initiatives has greatly influenced the India human papillomavirus vaccine market. The Indian government has taken proactive and comprehensive measures to tackle the public health challenge posed by human papillomavirus (HPV) infections. The primary goal of these initiatives is to increase awareness about the advantages of HPV vaccination and ensure broad vaccine coverage, with a specific focus on young girls and women. In addition to conducting awareness campaigns, the government has initiated vaccination programs and several educational initiatives to distribute information about HPV, its risks, and preventive measures.

In December 2022, the National Technical Advisory Group for Immunization (NTAGI) recommended the inclusion of the HPV vaccine in the Universal Immunization Programme (UIP). The plan involved a one-time catch-up vaccination for 9-14-year-old adolescent girls, followed by routine introduction at 9 years of age. To facilitate this vaccination drive, schools played a significant role in the implementation, adopting a grade-based approach for girls in 5th to 10th grades.

Quadrivalent Vaccines are Witnessing Rapid Growth in Demand

Increasing demand for quadrivalent vaccines has caused growth in India human papillomavirus vaccine market. The quadrivalent HPV vaccine consists of a combination of four HPV type-specific Virus-Like Particles (VLPs) derived from HPV 6, 11, 16, and 18 L1 proteins, along with an aluminum adjuvant. Clinical trials have demonstrated the vaccine's remarkable efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 in females who have not been previously infected with the respective HPV type. It is essential to note that the vaccine does not offer protection against diseases caused by HPV types that females may already be infected with at the time of vaccination. Gardasil, a quadrivalent vaccine developed by Merck & Co. in October 2022, revealed the initial results of the clinical trial to test for two versus three doses of Gardasil vaccine in India. The clinical trials were carried out by All India Institute of Medical Sciences, New Delhi, in collaboration with several other institutes and hospitals.

High Prevalence and Government Initiatives for HPV in Eastern Region

In the Eastern region, cervical cancer is growing at a rapid rate. The district of Papumpare in the Indian state of Arunachal Pradesh has the highest incidence rate of cervical cancer (AAR-27.7) in Asia, according to the National Cancer Registry Programme. Mizoram's Aizawl district came next, with an incidence of AAR-27.3, followed by Arunachal Pradesh's Pasighat district, with an incidence of AAR-20.3. To reduce the prevalence of HPV, the central and state governments have started various initiatives aimed towards increasing awareness about HPV and increasing immunization drives. For example, Sikkim state made a landmark decision to be the first state in India to introduce HPV vaccine statewide. In June 2023, the Union Health Ministry administered the human papillomavirus (HPV) vaccine in the Mizoram state as a part of the universal immunization program.

Future Market Scenario (2024 - 2031F)

Increased awareness and education campaigns regarding the link between HPV and cervical cancer in India are expected to boost the adoption rate of the vaccine in the India human papillomavirus vaccine market.

The India human papillomavirus vaccine market may be greatly impacted by the government's efforts to promote HPV vaccination, whether by including it in national immunization programs or by providing financial assistance.

Future advancements in vaccination science may lead to the development of HPV vaccinations that offer protection against new virus strains. As a result, the India human papillomavirus vaccine market may become more effective, increasing their public appeal, and maybe expanding the age range of individuals who can receive vaccinations.

Collaboration between vaccine producers, authorities, non-governmental organizations, and healthcare professionals in the India human papillomavirus vaccine market may expand the availability of HPV vaccines throughout the country, particularly in rural and impoverished areas.

Key Players Landscape and Outlook

India human papillomavirus vaccine market is undergoing a notable transformation, marked by a rising trend of mergers and collaborations among pharmaceutical firms and research institutions. These strategic partnerships are emerging as pivotal catalysts propelling the progress of HPV vaccine development, production, and distribution in India. Considering the increasing demand for HPV vaccines and the mounting recognition of their significance in cervical cancer and HPV-linked ailments, notable players within India's pharmaceutical sector are embracing the potency of collaboration.

For instance, in January 2023, India celebrated a significant milestone with the launch of its first domestically developed Quadrivalent Human Papillomavirus vaccine (qHPV) named 'CERVAVAC.' This achievement was made possible through a collaborative effort between the Serum Institute of India (SII), the Department of Biotechnology (DBT), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation. 'CERVAVAC' promises to play a crucial role in preventing HPV infections and associated diseases.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. India Human Papillomavirus Vaccine Market Outlook, FY2017-FY2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type
  • 4.2.1. Bivalent
  • 4.2.2. Quadrivalent
  • 4.2.3. Nonavalent
• 4.3. By Disease indication
  • 4.3.1. Cervical cancer
  • 4.3.2. Anal cancer
  • 4.3.3. Vulvar & Vaginal cancer
  • 4.3.4. Penile cancer
  • 4.3.5. Oropharyngeal cancer
  • 4.3.6. Others
• 4.4. By Method of Synthesis
  • 4.4.1. Nucleic acid-based
    • 4.4.1.1. DNA
    • 4.4.1.2. mRNA
  • 4.4.2. Peptide-based
  • 4.4.3. Protein-based
  • 4.4.4. Cell-based
  • 4.4.5. Live vector vaccine
• 4.5. By Distribution Channel
  • 4.5.1. Hospital
  • 4.5.2. Retail Pharmacy
  • 4.5.3. Online Pharmacy
  • 4.5.4. Non-Governmental Organizations
• 4.6. By Region
  • 4.6.1. North
  • 4.6.2. South
  • 4.6.3. East
  • 4.6.4. West and Central
• 4.7. By Company Market Share (%), FY2023

5. Market Mapping, FY2023

• 5.1. By Type
• 5.2. By Disease Indication
• 5.3. By Method of Synthesis
• 5.4. By Distribution Channel
• 5.5. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors (Challenges and Restraints)

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. Regulatory Approvals
• 8.4. Innovations/Emerging Technologies

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Appliable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. GlaxoSmithKline Plc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Merck & Co., Inc.
• 12.3. Beijing Health Guard Biotechnology, Inc.
• 12.4. China National Biotec Group Company Limited
• 12.5. Shanghai Bovax Biotechnology Co., Ltd.
• 12.6. Walvax Biotechnology Co., Ltd
• 12.7. Xiamen Innovax Biotech Co., Ltd.
• 12.8. Serum Institute of India Pvt. Ltd.
• 12.9. Eyegene Inc.
• 12.10. Janssen Biotech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Human Papillomavirus Vaccine Market, By Value, in USD Billion, FY2017-FY2031F
• Figure 2. India Human Papillomavirus Vaccine Market, By Volume, in Thousand Units, FY2017-FY2031F
• Figure 3. India Human Papillomavirus Vaccine Market Share (%), By Type, FY2017-FY2031F
• Figure 4. India Human Papillomavirus Vaccine Market Share (%), By Disease Indication, FY2017-FY2031F
• Figure 5. India Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, FY2017-FY2031F
• Figure 6. India Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, FY2017-FY2031F
• Figure 7. India Human Papillomavirus Vaccine Market Share (%), By Region, FY2017-FY2031F
• Figure 8. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 9. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 10. By Method of Synthesis Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 11. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 12. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2023